TY - JOUR
T1 - Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT
AU - on behalf of the Infectious Diseases Working Party EBMT
AU - Styczynski, Jan
AU - Tridello, Gloria
AU - Gil, Lidia
AU - Ljungman, Per
AU - Mikulska, Malgorzata
AU - Ward, Katherine N.
AU - Cordonnier, Catherine
AU - de la Camara, Rafael
AU - Averbuch, Diana
AU - Knelange, Nina
AU - Socié, Gerard
AU - Chevallier, Patrice
AU - Blaise, Didier
AU - Yakoub-Agha, Ibrahim
AU - Forcade, Edouard
AU - Cornelissen, Jan
AU - Maertens, Johan
AU - Petersen, Eefke
AU - Nguyen-Quoc, Stéphanie
AU - Veelken, Hendrik
AU - Schaap, Nicolaas
AU - Passweg, Jakob
AU - Michallet, Mauricette
AU - Fegueux, Nathalie
AU - Deconinck, Eric
AU - Russell, Nigel
AU - Basak, Grzegorz
AU - Bader, Peter
AU - Montoto, Silvia
AU - Kröger, Nicolaus
AU - Cesaro, Simone
PY - 2019/1/1
Y1 - 2019/1/1
N2 - The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997–2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D− (HR = 1.21; p = 0.044), and R−/D + (HR = 1.21; p = 0.048) in comparison to R−/D− transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R−/D−): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.
AB - The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997–2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D− (HR = 1.21; p = 0.044), and R−/D + (HR = 1.21; p = 0.048) in comparison to R−/D− transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R−/D−): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.
UR - http://www.scopus.com/inward/record.url?scp=85069895837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069895837&partnerID=8YFLogxK
U2 - 10.1038/s41409-019-0627-9
DO - 10.1038/s41409-019-0627-9
M3 - Article
AN - SCOPUS:85069895837
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
ER -